NCT00911157 - The Treatment of Acute Deep Vein Thrombosis (DVT) of GSK576428 (Fondaparinux Sodium) in Japanese Patients | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 30, 2008

Primary Completion Date

November 30, 2009

Study Completion Date

November 30, 2009

Conditions

Thrombosis, Venous

Interventions

DRUG

Fondaparinux sodium

The dose of Fondaparinux will be determined based on a subject's body weight (\< 50 kg, 5 mg; 50 to 100 kg, 7.5 mg; \>100 kg, 10 mg) and administered once daily by subcutaneous (SC) injection.

DRUG

unfractionated heparin (UFH)

UFH therapy will be started on Day 1 while adjusting activated partial thromboplastin time (aPTT) to maintain aPTT 1.5 to 2.5 times control.

Trial Locations (24)

440-8510

GSK Investigational Site, Aichi

802-8555

GSK Investigational Site, Fukuoka

370-0829

GSK Investigational Site, Gunma

371-8511

GSK Investigational Site, Gunma

720-8520

GSK Investigational Site, Hiroshima

739-0651

GSK Investigational Site, Hiroshima

006-8555

GSK Investigational Site, Hokkaido

060-8543

GSK Investigational Site, Hokkaido

060-8648

GSK Investigational Site, Hokkaido

654-0155

GSK Investigational Site, Hyōgo

305-8576

GSK Investigational Site, Ibaraki

311-3193

GSK Investigational Site, Ibaraki

892-0853

GSK Investigational Site, Kagoshima

245-8575

GSK Investigational Site, Kanagawa

860-0008

GSK Investigational Site, Kumamoto

860-8556

GSK Investigational Site, Kumamoto

514-8507

GSK Investigational Site, Mie

399-0021

GSK Investigational Site, Nagano

859-3615

GSK Investigational Site, Nagasaki

951-8520

GSK Investigational Site, Niigata

701-1192

GSK Investigational Site, Okayama

430-8558

GSK Investigational Site, Shizuoka

438-8550

GSK Investigational Site, Shizuoka

113-8655

GSK Investigational Site, Tokyo